Inspire Medical Systems (INSP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.14
- Estimate
- -$0.25
- Surprise
- +157.1%
- Revenue (period 2026-06-30)
- $200.6M
- Score at report (before → after)
- 4.8 → 4.8/10
Revenue source: xbrl.
How the report landed
Inspire Medical Systems (INSP) beat the -$0.25 estimate with diluted EPS of $0.14 — a large 157.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (4.8/10) to Hold at 4.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INSP Sell at 4.8/10.
4 of the last 4 quarters beat the estimate; this quarter's +157.1% surprise compares with a +190.3% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: Inspire system
- Earnings expected to decline ~66% (cyclical peak)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $73.00
- Price target
- $83.95
- Stop
- $67.89
- Upside to target
- +15.0%
Forward estimates sit below the trailing run-rate (47.5× forward vs 16.1× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 2.4× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
INSP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.11B
- P/E (fwd)
- 47.5
- P/E (ttm)
- 16.1
- 52-week range
- $38.91–$147.03
- Off 52-week high
- 50.4%
- RSI (14)
- 74
- Volume vs avg
- 2.39×
- Score today
- 4.8/10